NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor

Trial Profile

NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2014

At a glance

  • Drugs NGR-TNF (Primary) ; Cisplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MolMed
  • Most Recent Events

    • 03 Jan 2012 Additional lead trial investigator (Antonio Lambaise) identified as reported by ClinicalTrials.gov.
    • 14 Feb 2011 Results published in Clinical Cancer Research.
    • 24 Sep 2009 Long-term follow-up results have been presented at the joint Annual Meeting of the European Cancer Organisation and of the European Society of Medical Oncology (ECCO-ESMO), according to a MolMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top